UNICA IRIS Institutional Research Information System

CARTA, MANOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 189.805
NA - Nord America 6.525
AS - Asia 2.910
SA - Sud America 403
AF - Africa 70
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 199.722
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 188.175
US - Stati Uniti d'America 6.438
SG - Singapore 1.179
CN - Cina 955
UA - Ucraina 373
SE - Svezia 333
BR - Brasile 321
DE - Germania 290
VN - Vietnam 264
FI - Finlandia 168
GB - Regno Unito 152
FR - Francia 139
HK - Hong Kong 103
KR - Corea 87
IN - India 82
CA - Canada 50
NL - Olanda 37
IQ - Iraq 35
AR - Argentina 34
RU - Federazione Russa 29
BD - Bangladesh 27
ES - Italia 27
JP - Giappone 27
MX - Messico 22
TR - Turchia 19
ID - Indonesia 17
PK - Pakistan 16
ZA - Sudafrica 16
BE - Belgio 15
SA - Arabia Saudita 15
VE - Venezuela 14
PH - Filippine 13
PL - Polonia 13
CZ - Repubblica Ceca 12
CO - Colombia 11
AT - Austria 10
EG - Egitto 10
MA - Marocco 10
AE - Emirati Arabi Uniti 9
KE - Kenya 9
JO - Giordania 6
PY - Paraguay 6
TH - Thailandia 6
TW - Taiwan 6
AZ - Azerbaigian 5
CL - Cile 5
MY - Malesia 5
NZ - Nuova Zelanda 5
PE - Perù 5
PS - Palestinian Territory 5
RO - Romania 5
TN - Tunisia 5
UZ - Uzbekistan 5
EC - Ecuador 4
IE - Irlanda 4
LB - Libano 4
LT - Lituania 4
NP - Nepal 4
AO - Angola 3
AU - Australia 3
BB - Barbados 3
DZ - Algeria 3
PA - Panama 3
SN - Senegal 3
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
IR - Iran 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MN - Mongolia 2
NG - Nigeria 2
NO - Norvegia 2
SK - Slovacchia (Repubblica Slovacca) 2
BH - Bahrain 1
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GM - Gambi 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MT - Malta 1
MU - Mauritius 1
OM - Oman 1
PT - Portogallo 1
Totale 199.718
Salva come PNG Salva come JPEG
Città #
Cagliari 176.497
Uta 11.295
Fairfield 721
Ashburn 620
Singapore 605
Woodbridge 554
Chandler 411
Houston 377
San Jose 355
Ann Arbor 306
Boardman 250
Seattle 243
Wilmington 241
Cambridge 233
Dallas 215
Nyköping 201
Beijing 198
Jacksonville 198
Dearborn 121
Los Angeles 107
Santa Clara 101
Helsinki 96
Hong Kong 94
The Dalles 93
Ho Chi Minh City 90
Hefei 86
Seoul 86
Nanjing 79
Shanghai 79
Lauterbourg 71
Council Bluffs 68
New York 67
Hanoi 56
Boston 48
San Diego 45
Milan 39
Buffalo 35
Munich 35
Guangzhou 28
Frankfurt am Main 24
Redwood City 24
Tokyo 24
Orem 23
São Paulo 21
Falls Church 20
Shenyang 20
Tianjin 19
Dong Ket 18
London 18
Norwalk 18
Redondo Beach 18
Rome 18
Phoenix 17
Toronto 17
Montreal 16
Baghdad 15
Hebei 15
Nuremberg 15
Washington 15
Chennai 14
Mountain View 14
Verona 14
Brussels 13
Changsha 13
Sassari 13
Amsterdam 12
Chicago 12
Da Nang 12
Düsseldorf 12
Jiaxing 12
Orange 12
San Francisco 12
Stockholm 12
Brooklyn 11
Denver 11
Padova 11
Turku 11
Brno 10
Hangzhou 10
Mumbai 10
Pisa 10
Atlanta 9
Dhaka 9
Haiphong 9
Nanchang 9
Pune 9
Zhengzhou 9
Manchester 8
Porto Alegre 8
Riyadh 8
San Mateo 8
Columbus 7
Hải Dương 7
Johannesburg 7
Nairobi 7
New Delhi 7
Rio de Janeiro 7
Taizhou 7
Warsaw 7
Amman 6
Totale 195.828
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson's disease 24.353
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease 7.290
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction 5.816
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats 4.627
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia 4.525
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. 4.330
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.291
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease 4.075
Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT 1A, but not 5-HT 2 receptor activation 3.727
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? 3.726
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia 3.687
Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats 3.578
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.544
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation 3.457
Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat's tissues 3.410
Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine 3.374
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Parkinson's disease: a preliminary finding 3.342
Vitamin A deficiency produces spatial learning and memory impairment in rats 3.260
null 2.940
Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats 2.870
VGF peptides as novel biomarkers in Parkinson’s disease 2.755
Biphasic effects of ethanol on acetylcholine release in the rat prefrontal cortex 2.669
Amphetamine usage, misuse, and addiction processes: an overview 2.638
Augmented cocaine-induced accumbal dopamine efflux, motor activity and place preference in rats fed with a tryptophan-deficient diet 2.619
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia 2.580
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease 2.570
The serotonergic system in levodopa-induced dyskinesia 2.559
Optimization of continuous in vivo DOPA production and studies of ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats 2.371
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding 2.361
Startle Reflex as a possible biomarker associated with REM sleep behavior disorders in the prodromal stage of Parkinson's disease 2.341
null 2.298
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration 2.293
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease 2.265
Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson's Disease 2.265
Modulation of the Startle Response in REM Sleep Behavior Disorder 2.258
null 2.247
5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation 2.237
Foetal cell transplantation for Parkinson's disease: focus on graft-induced dyskinesia 2.191
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations 2.168
Role of serotonin neurons in L-DOPA- and graft-induced dyskinesia in a rat model of parkinson's disease 2.166
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson's disease 2.162
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: A correlation study 2.155
The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients 2.012
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats 1.927
Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia 1.783
L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease 1.765
null 1.663
null 1.607
null 1.604
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and5-HT1B receptor agonists in the rat Parkinson model 1.547
null 1.471
Dyskinesia in Parkinson’s disease: a clinical complication and an open scientific question 1.426
BDNF Overexpression Increases Striatal D3Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia 1.409
Role of serotonin neurons in the induction of L-DOPA- and graft-induced dyskinesias in Parkinson´s disease 1.392
Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease 1.257
Transcriptome analysis in a rat model of L-dopa-induced dyskinesia 1.244
Nurr1 is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons 1.240
A simple method for large-scale generation of dopamine neurons from human embryonic stem cells 1.240
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update 1.207
Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine 1.111
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease 1.107
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease 1.087
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms 1.086
The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons 1.083
Vitamin A deficiency affects neither frontocortical acetylcholine nor working memory 971
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia 954
Involvement of the serotonin system in L-DOPA-induced dyskinesias 947
Effects of tryptophan deficiency on prepulse inhibition of the acoustic startle in rats 930
Critical involvement of cAMP/DARPP-32 and ERK signaling in L-DOPA-induced dyskinesia 900
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease 832
Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease 832
Altered dopaminergic innervation and amphetamine response in adult Otx2 conditional mutant miceAberrant accumbal innervation and sensitized motor response to amphetamine in Otx2 conditional mutant mice 823
null 780
Pharmacological validation of a mouse model of L-dopa-induced dyskinesia 746
Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression 738
Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation 710
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats 694
Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy 672
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective 615
null 565
Perturbation of serine enantiomers homeostasis in the striatum of MPTP-lesioned monkeys and mice reflects the extent of dopaminergic midbrain degeneration 528
null 475
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy 428
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats 421
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients 367
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia 322
null 320
Expanding the therapeutic potential of neuro(active)steroids: a promising strategy for hyperdopaminergic behavioral phenotypes 249
Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease 193
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease 165
The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease 112
Early Dopaminergic Dysfunction Induces PRO-VGF Changes in Blood and Brain of Rats with Alpha-Synuclein Overexpression 81
VGF INVOLVEMENT ON PARKINSON’S DISEASE 26
Totale 200.054
Salva come PNG Salva come JPEG
Categoria #
all - tutte 234.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 234.636
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.919 0 0 0 0 0 0 0 0 0 0 1.875 1.044
2021/20227.370 719 760 434 332 526 628 560 320 524 804 895 868
2022/202311.709 921 1.307 1.260 1.031 1.015 1.085 600 957 847 907 1.217 562
2023/202412.241 416 406 378 630 1.108 1.739 1.846 1.090 483 861 1.329 1.955
2024/202578.427 28.618 18.312 23.829 2.498 1.247 1.314 1.564 121 289 202 172 261
2025/20265.772 427 204 558 543 521 468 1.675 358 426 553 39 0
Totale 200.054